Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Abstract

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 3 -R 6 , R 11 , B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

1 . A compound of Formula I:  
       
         
           
           
               
               
           
         
       
       or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: 
 W is hydrogen, R 1 , R 1 OC(O), R 1 C(O), R 1 (CH 2 ) s NHC(O), R 1 S(O) 2 , or (R 1 ) 2 CH(CH 2 ) s NHC(O), wherein s is 0-4;  
 R 1  is 
 R 2 ,  
 R 2 (CH 2 ) 1 C(R 12 ) 2 , where t is 0-3, and each R 12  can be the same or different,  
 (R 2 )(OR 12 )CH(CH 2 ) p , where p is 1-4,  
 (R 2 ) 2 (OR 12 )C(CH 2 ) p , where p is 1-4,  
 R 2 C(R 12 ) 2 (CH 2 ) 1 , wherein t is 0-3, and each R 12  can be the same or different, wherein (R 12 ) 2  can also form a ring with C represented by C 3-9  cycloalkyl,  
 R 2 CF 2 C(R 12 ) 2 (CH 2 ) q , wherein q is 0-2, and each R 12  can be the same or different, wherein (R 12 ) 2  can also form a ring with C represented by C 3-9 cycloalkyl,  
 R 2 CH 2 C(R 12 ) 2 (CH 2 ) q , wherein q is 0-2, and each R 12  can be the same or different, wherein (R 12 ) 2  can also form a ring with C represented by C 3-9  cycloalkyl,  
 (R 2 ) 2 CH(CH 2 ) r , where r is 0-4 and each R 2  can be the same or different, and wherein (R 2 ) 2  can also form a ring with CH represented by C 3-9  cycloalkyl, C 7-12  bicylic alkyl, C 10-16  tricylic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,  
 R 2 O(CH 2 ) p , wherein p is 2-4,  
 (R 2 ) 2 CF(CH 2 ) r , wherein r is 0-4 and each R 12  can be the same different, wherein (R 12 ) 2  can also form a ring with C represented by C 3-9  cycloalkyl, C 7-12  bicyclic alkyl, C 10-16  tricyclic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,  
                     where s is 0 or 1, or    
 R 2 CF 2 C(R 12 ) 2 ;  
 
 R 2  is 
 phenyl, naphthyl, or biphenyl, each of which is unsubstituted or substituted with one or more of C 1-4  alkyl, C 1-4  alkoxy, halogen, hydroxy, CF 3 , OCF 3 , COOH, CONH 2 , or SO 2 NH 2 ,  
 a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring or non-heterocyclic ring which can be saturated or unsaturated, wherein the heterocyclic ring contains from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the heterocyclic or non-heterocyclic ring is unsubstituted or substituted with halogen or hydroxy,  
 C 1-12  alkyl, unsubstituted or substituted with one or more of hydroxy, COOH, amino, optionally C 1-3  alkyl substituted aryl, C 3-9  cycloalkyl, CF 3 , N(CH 3 ) 2 , heteroaryl, or heterocycloalkyl,  
 CF 3 ,  
 C 3-9  cycloalkyl, unsubstituted or substituted with aryl,  
 C 7-12  bicyclic alkyl, or  
 C 10-16  tricyclic alkyl;  
 
 Y is —NH— or —O—;  
 R 3 , R 4 , R 5  and R 6  are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, haloalkyl, hydroxy, alkoxy, aryloxy, heteroaryloxy, halogen, haloalkoxy, hydroxyalkyl, cyano, nitro, —CO 2 R x , —CH 2 OR x  or —OR x , 
 where R x , in each instance, is independently one of hydrogen, C 1-12  alkyl or C 3-9  cycloalkyl wherein said C 1-12  alkyl or C 3-9  cycloalkyl groups may optionally have one or more unsaturations;  
 
 R 11  is hydrogen, alkyl, or alkenyl;  
 R 12  is 
 hydrogen or halogen,  
 phenyl, naphthyl, or biphenyl, each of which is unsubstituted or substituted with one or more of C 1-4  alkyl, C 1-4  alkoxy, halogen, hydroxy, CF 3 , OCF 3 , COOH, or CONH 2 ,  
 a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to four heteroatoms selected from the group consisting of N, O and S,  
 C 1-12  alkyl, unsubstituted or substituted with one or more of hydroxy, COOH, amino, C 6-14  aryl, heteroaryl, or heterocycloalkyl,  
 CF 3 ,  
 C 3-9  cycloalkyl,  
 C 7-12  bicyclic alkyl, or  
 C 10-16  tricyclic alkyl;  
 
 B is selected from the group consisting of:  
                     
 wherein  
 R 7 , R 8 , R 9 , and R 10  are independently hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl or carboxyalkyl; 
 or R 7  and R 8  are taken together to form —(CH 2 ) u —, where u is 2 to 7, preferably 2 to 5, while R 9  and R 10  are defined as above;  
 or R 9  and R 10  are taken together to form —(CH 2 ) v —, where v is 2 to 7, preferably 2 to 5, while R 7  and R 8  are defined as above;  
 or R 7  and R 9  are taken together to form —(CH 2 ) y —, where y is 0 (a bond) or 1 to 7, preferably 0-4, while R 8  and R 10  are defined as above;  
 
 X is —O—, —N 18 —, or —CH═N— (where N is bonded to NR 13 ) where R 18  is hydrogen, alkyl, cycloalkyl or aryl, wherein said alkyl, cycloalkyl or aryl are optionally substituted with amino, monoalkylamino, dialkylamino, alkoxy, hydroxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, aryl, heteroaryl, acylamino, cyano or trifluoromethyl;  
 R a , R b  and R c  are independently hydrogen, alkyl, hydroxy, alkoxy, aryloxy, aralkoxy, alkoxycarbonyloxy, cyano or —CO 2 R w , where R w  is C 1-12  alkyl, C 3-9  cycloalkyl, C 6-14  aryl, C 6-14 ar(C 1-12 ) alkyl,  
                     where R e  and R f  are independently hydrogen, C 1-6  alkyl, C 2-6  alkenyl or C 6-14  aryl, R g  is hydrogen, C 1-6  alkyl, C 2-6  alkenyl or C 6-14  aryl, R h  is hydrogen, C 1-6  alkyl, C 2-6  alkenyl or C 6-14  aryl, and R i  is C 6-14  ar(C 1-12 )alkyl or C 1-6  alkyl;    
 n is from zero to 8; and  
 m is from zero to 6;  
 R 13  is hydrogen, alkyl, alkenyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl or carboxyalkyl;  
 R 14  and R 15  are independently hydrogen, alkyl, cycloalkyl, halogen or alkoxy; and  
 R 16  and R 17  are independently hydrogen, alkyl, hydroxy, alkoxy, aryloxy, alkoxycarbonyl, cyano or —CO 2 R j , where R j  is C 1-12  alkyl, C 3-9  cycloalkyl, C 6-14  aryl, C 6-14 ar(C 1-12 )alkyl, halo(C 1-12 )alkyl or  
                     where R e , R f  and R g  are independently hydrogen or C 1-12  alkyl.    
 
     
     
         2 . A compound of  claim 1 , wherein 
 R 3 , R 4 , R 5  and R 6  are independently hydrogen, C 1-12  alkyl, C 3-9  cycloalkyl, halogen, C 2-20  alkenyl, C 2-20  alkynyl, optionally substituted C 6-14  aryl, optionally substituted C 6-14 ar(C 1-12 )alkyl, optionally substituted heteroaryl, halo(C 1-12 )alkyl, C 1-12  alkoxy, C 6-14  aryloxy, heteroaryloxy, halo(C 1-20 )alkoxy or hydroxy(C 1-12 )alkyl;    R 11  is hydrogen, C 1-12  alkyl or C 2-20  alkenyl;    R 7 , R 8 , R 9  and R 10  are independently hydrogen, C 1-12  alkyl, C 6-14 ar(C 1-12 )alkyl, C 6-14 aryl, hydroxy(C 1-12 )alkyl, amino(C 1-12 )alkyl, mono(C 1-12 )alkylamino(C 1-12 )alkyl, di(C 1-12 )alkylamino(C 1-12 )alkyl, or carboxy(C 1-12 )alkyl;    R 18  is C 1-12  alkyl, C 3-9  cycloalkyl or C 6-14  aryl, each of which is optionally substituted with amino, mono(C 1-12 )alkylamino, di(C 1-12 )alkylamino, C 1-20  alkoxy, hydroxy, carboxy, C 1-20 alkoxycarbonyl, C 6-14  aryloxycarbonyl, C 6-14 ar(C 1-20 )alkoxycarbonyl, C 6-14  aryl, C 5-10  heteroaryl, acylamino, cyano or trifluoromethyl;    R a , R b  and R c  are independently C 1-12  alkyl, C 1-20  alkoxy, C 6-14  aryloxy, C 6-14 ar(C 1-20 )alkoxy, or C 1-20  alkoxycarbonyloxy;    R 13  is C 1-12  alkyl, C 1-20  alkoxy, C 6-14  aryloxy or C 1-20  alkoxycarbonyl;    R 14  and R 15  are independently C 1-12  alkyl, C 3-9  cycloalkyl or C 1-20  alkoxy; and    R 16  and R 17  are independently C 1-12  alkyl, C 1-20  alkoxy, C 6-14  aryloxy or C 1-20  alkoxycarbonyl.    
     
     
         3 . A compound according to  claim 1 , wherein B is  
       
         
           
           
               
               
           
         
       
     
     
         4 . A compound according to  claim 1 , wherein B is  
       
         
           
           
               
               
           
         
       
     
     
         5 . A compound according to  claim 1 , wherein Y is —NH—.  
     
     
         6 . A compound according to  claim 1 , wherein W is R 1  or R 1 S(O) 2 , where R 1  is R 2  and R 2  is either optionally substituted aryl or C 1-7  alkyl substituted with aryl.  
     
     
         7 . A compound according to  claim 1 , wherein W is R 1 , where R 1  is R 2  or R 2 CF 2 C(R 12 ) 2 (CH 2 ) q , and R 2  is either optionally substituted aryl or C 1-7  alkyl substituted with aryl; R 12  is hydrogen; and q is zero.  
     
     
         8 . A compound according to  claim 1 , wherein R 6  is C 1-6  alkyl or halogen.  
     
     
         9 . A compound according to  claim 8 , wherein R 6  is methyl, chloro or fluoro.  
     
     
         10 . A compound according to  claim 9 , wherein R 6  is chloro while R 3  is fluoro or hydroxy.  
     
     
         11 . A compound according to  claim 1 , wherein R 11  is hydrogen.  
     
     
         12 . A compound according to  claim 1 , wherein R a , R b , R c  and R 13  are each hydrogen.  
     
     
         13 . A compound according to  claim 1 , wherein each of R 7 , R 8 , R 9  and R 10  are hydrogen.  
     
     
         14 . A compound of  claim 1 , which is one of: 
 N-[2-Amidinoaminooxy)ethyl]-2-{3-[(2,2-difluoro-2-phenylethyl)amino]-6-chloro-2-fluorophenyl}acetamide;    N-[(6-Amino-2-methyl(3-pyridyl))methyl]-2-{3-[(2,2-difluoro-2-phenylethyl)amino]-6-chloro-2-fluorophenyl}acetamide;    N-(6-Amino-2,4-dimethyl(3-pyridyl))methyl]-2-{3-[(2,2-difluoro-2-phenylethyl}acetamide;    N-[2-(Amidinoaminooxy)ethyl]-2-(3-{[2,2-difluoro-2-(4-fluoronaphthyl)ethyl]amino}-6-chloro-2-fluorophenyl)acetamide;    N-[(6-Amino-2-methyl(3-pyridyl))methyl]-2-{[2,2-difluoro-2-(4-fluoronaphthyl)ethyl]amino}-6-chloro-2-fluorophenyl)acetamide;    N-2-(guanidinooxy)ethyl]-2-(3 {[benzylsulfonyl]amino}phenyl)acetamide;    N-[2-(Guanidinooxy)ethyl]-2-(2-chloro-5-{[benzylsulfonyl]amino}phenyl)acetamide;    N-[2-(Guanidinooxy)ethyl]-2-(2-methyl-5-{[benzylsulfonyl]amino}phenyl)acetamide;    N-[2-(Guanidinooxy)ethyl]-2-(2-hydroxy-6-methyl-3-{[(3-methylphenyl)sulfonyl]amino}phenyl)acetamide;    N-[(6-Amino-2-methyl(3-pyridyl))methyl]-2-(2-hydroxy-6-methyl-3-{[(3-methylphenyl)sulfonyl]amino}phenyl)acetamide; or    N-({N-[2-(Guanidinooxy)ethyl]carbamoyl}methyl)-2-hydroxy-4-methylphenyl 3-methylbenzenesulfonate;    or a solvate, hydrate or pharmaceutically acceptable salt thereof    
     
     
         15 . A pharmaceutical composition, comprising a compound of  claim 1  and a pharmaceutically-acceptable carrier.  
     
     
         16 . A pharmaceutical composition, comprising a compound of  claim 3  and a pharmaceutically-acceptable carrier.  
     
     
         17 . A pharmaceutical composition, comprising a compound of  claim 4  and a pharmaceutically-acceptable carrier.  
     
     
         18 . A pharmaceutical composition, comprising a compound of  claim 14  and a pharmaceutically-acceptable carrier.  
     
     
         19 . A pharmaceutical composition according to  claim 15 , further comprising at least one of an anticoagulant, an antiplatelet agent or a thrombolytic agent.  
     
     
         20 . A pharmaceutical composition according to  claim 15 , wherein said compound is present in an amount between about 0.1 and about 500 mg.  
     
     
         21 . A method of inhibiting or treating aberrant proteolysis, thrombosis, ischemic, stroke, restenosis or inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of  claim 1 .  
     
     
         22 . A method of inhibiting or treating aberrant proteolysis, thrombosis, ischemic, stroke, restenosis or inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of  claim 3 .  
     
     
         23 . A method of inhibiting or treating aberrant proteolysis, thrombosis, ischemic, stroke, restenosis or inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of  claim 4 .  
     
     
         24 . A method of inhibiting or treating aberrant proteolysis, thrombosis, ischemic, stroke, restenosis or inflammation in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of  claim 14 .  
     
     
         25 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 15 .  
     
     
         26 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 16 .  
     
     
         27 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 17 .  
     
     
         28 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 18 .  
     
     
         29 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 19 .  
     
     
         30 . A method for the treatment or prophylaxis of states characterized by abnormal venous or arterial thrombosis involving either thrombin production or action in a mammal in need thereof, comprising administering to said mammal a composition of  claim 20 .  
     
     
         31 . A medical device for use in blood collection, blood storage or blood circulation, comprising a compound of  claim 1  embedded in or physically attached to said medical device.  
     
     
         32 . A medical device for use in blood collection, blood storage or blood circulation, comprising a compound of  claim 3  embedded in or physically attached to said medical device.  
     
     
         33 . A medical device for use in blood collection, blood storage or blood circulation, comprising a compound of  claim 4  embedded in or physically attached to said medical device.  
     
     
         34 . A medical device according to  claim 31 , which is a catheter, stent, blood dialysis machine, blood collection syringe or tube, or a blood line.  
     
     
         35 . A method of inhibiting the action of a proteolytic enzyme, comprising contacting said enzyme with a compound of  claim 1 .  
     
     
         36 . A method of inhibiting the action of a proteolytic enzyme, comprising contacting said enzyme with a compound of  claim 3 .  
     
     
         37 . A method of inhibiting the action of a proteolytic enzyme, comprising contacting said enzyme with a compound of  claim 4 .  
     
     
         38 . A method according to  claim 35 , wherein said enzyme is leukocyte neutrophil elastase, chymotrypsin, trypsin, urokinase, plasminogen activator, pancreatic elastase, cathepsin G, thrombin or factor Xa.  
     
     
         39 . A method according to  claim 36 , wherein said enzyme is leukocyte neutrophil elastase, chymotrypsin, trypsin, urokinase, plasminogen activator, pancreatic elastase, cathepsin G, thrombin or factor Xa.  
     
     
         40 . A method according to  claim 37 , wherein said enzyme is leukocyte neutrophil elastase, chymotrypsin, trypsin, urokinase, plasminogen activator, pancreatic elastase, cathepsin G, thrombin or factor Xa.  
     
     
         41 . A pharmaceutical composition according to  claim 15  adapted for oral administration.  
     
     
         42 . A pharmaceutical composition according to  claim 16  adapted for oral administration.  
     
     
         43 . A pharmaceutical composition according to  claim 17  adapted for oral administration.  
     
     
         44 . A pharmaceutical composition according to  claim 18  adapted for oral administration.  
     
     
         45 . A pharmaceutical composition according to  claim 19  adapted for oral administration.  
     
     
         46 . A pharmaceutical composition according to  claim 20  adapted for oral administration.